Rapid SARS-CoV-2 Seroprevalence Survey in Central and Western Divisions of Fiji, 2021

During November–December 2021, we performed a SARS-CoV-2 seroprevalence survey in Central and Western Divisions of Fiji. A total of 539 participants 8–70 years of age were 95.5% (95% CI 93.4%–97.1%) seropositive, indicating high community levels of immunity. Seroprevalence studies can inform public...

Descripción completa

Detalles Bibliográficos
Autores principales: Curtis, Stephanie J., Shah, Abdul W., Ratu, Ana, Wilson, Donald J., Hill, Philip C., Hulcome, Phil, Gaylard, Cathy, Faktaufon, Daniel, Cabemaiwai, Talica, Rabukawaqa, Isireli, Qoriniasi, Tevita, Narayan, Akesh, Nakalevu, Susana, Romakin, Pablo, Tudravu, Jemesa, Fong, James, Walsh, Nick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Centers for Disease Control and Prevention 2023
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9796197/
https://www.ncbi.nlm.nih.gov/pubmed/36573643
http://dx.doi.org/10.3201/eid2901.221514
Descripción
Sumario:During November–December 2021, we performed a SARS-CoV-2 seroprevalence survey in Central and Western Divisions of Fiji. A total of 539 participants 8–70 years of age were 95.5% (95% CI 93.4%–97.1%) seropositive, indicating high community levels of immunity. Seroprevalence studies can inform public health responses to emerging SARS-CoV-2 variants.

Ejemplares similares